<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141119</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.07.471580</article-id>
<article-id pub-id-type="archive">PPR430756</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Predictive profiling of SARS-CoV-2 variants by deep mutational learning</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Taft</surname>
<given-names>Joseph M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weber</surname>
<given-names>Cédric R.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Beichen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ehling</surname>
<given-names>Roy A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Jiami</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frei</surname>
<given-names>Lester</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Metcalfe</surname>
<given-names>Sean W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yermanos</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelton</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reddy</surname>
<given-names>Sai T.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Biosystems Science and Engineering, ETH Zurich, Basel 4058, Switzerland</aff>
<aff id="A2">
<label>2</label>Botnar Research Centre for Child Health, Basel 4058, Switzerland</aff>
<aff id="A3">
<label>3</label>deepCDR Biologics AG, Basel 4058, Switzerland</aff>
<aff id="A4">
<label>4</label>Department of Biology, Institute of Microbiology and Immunology, ETH Zurich, Zurich 8093, Switzerland</aff>
<aff id="A5">
<label>5</label>Department of Pathology and Immunology, University of Geneva, Geneva 1211, Switzerland</aff>
<aff id="A6">
<label>6</label>Te Huataki Waiora School of Health, University of Waikato, Hamilton 3240, New Zealand</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>Correspondence: <email>sai.reddy@ethz.ch</email>
</corresp>
<fn id="FN1" fn-type="equal">
<label>*</label>
<p id="P1">Equal contribution</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>09</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P2">The continual evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the emergence of variants that show resistance to vaccines and neutralizing antibodies (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R4">4</xref>) threaten to prolong the coronavirus disease 2019 (COVID-19) pandemic (<xref ref-type="bibr" rid="R5">5</xref>). Selection and emergence of SARS-CoV-2 variants are driven in part by mutations within the viral spike protein and in particular the ACE2 receptor-binding domain (RBD), a primary target site for neutralizing antibodies. Here, we develop deep mutational learning (DML), a machine learning-guided protein engineering technology, which is used to interrogate a massive sequence space of combinatorial mutations, representing billions of RBD variants, by accurately predicting their impact on ACE2 binding and antibody escape. A highly diverse landscape of possible SARS-CoV-2 variants is identified that could emerge from a multitude of evolutionary trajectories. DML may be used for predictive profiling on current and prospective variants, including highly mutated variants such as omicron (B.1.1.529), thus supporting decision making for public heath as well as guiding the development of therapeutic antibody treatments and vaccines for COVID-19.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P3">As of late 2021, variants of SARS-CoV-2 associated with higher transmissibility and/or immune evasion (antibody escape) have almost entirely supplanted the original founder strain (Wu-Hu-1) (<xref ref-type="bibr" rid="R6">6</xref>). Emerging variants often possess at least one mutation in the RBD (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>), which can directly influence binding to ACE2 (<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>). For example, alpha (B.1.1.7), beta and gamma variants all possess the N501Y mutation, which is associated with higher affinity binding to ACE2 (<xref ref-type="bibr" rid="R12">12</xref>), suggesting this may represent a possible selective pressure for variant emergence.</p>
<p id="P4">Neutralizing antibodies, including monoclonal antibody therapeutics and those induced by vaccination (with the original Wu-Hu-1 spike protein), often display reduced binding and neutralization to variants. Detailed molecular analysis has revealed that many neutralizing antibodies to SARS-CoV-2 share sequence and structural features (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R17">17</xref>), which has led to their categorization into four common classes defined by groups of targeted RBD epitopes (<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R18">18</xref>). For example, class 1 antibodies include the clinically approved REGN10933 (casirivimab) (<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>) and LY-CoV16 (etesevimab) (<xref ref-type="bibr" rid="R21">21</xref>). Circulating variants with mutations in position K417 [e.g., beta, gamma and delta plus (B.1.617.2 + K417N)] as well as the mink-selected Y453F mutation (Cluster 5) display decreased neutralization by these class 1 antibodies (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R22">22</xref>). Class 2 neutralizing antibodies including the clinically used LY-CoV555 (bamlanivimab) also strongly inhibit ACE2 binding, however, variants such as beta, gamma, eta (B.1.525), kappa (B.1617.1) and iota (B1.526) all possess the RBD mutation E484K/Q that can lead to a substantial loss of binding and neutralization. Class 3 antibodies, including the clinically approved REGN10987 (imdevimab) and S309 (sotrovimab) (<xref ref-type="bibr" rid="R23">23</xref>), bind partially conserved epitopes and have so far retained binding to most circulating variants, with the exception of the N439K mutation, which reduces binding of REGN10987 by 28-fold (<xref ref-type="bibr" rid="R24">24</xref>). Class 4 antibodies such as CR3022 target a highly conserved epitope among sarbecoviruses (<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>), and are therefore largely resistant to escape variants, but generally lack neutralizing potency since they do not directly inhibit ACE2 binding. This clustering of human neutralizing antibodies into discrete epitope-binding classes further suggests that the evolution of SARS-CoV-2 may converge via mutations that provide escape to these common antibody classes, which could result in variants with immune evasion.</p>
<p id="P5">Bloom and colleagues have performed yeast surface display and deep mutational scanning (DMS) (<xref ref-type="bibr" rid="R28">28</xref>) on the entire 201 amino acid RBD of SARS-CoV-2 in order to determine the impact of single-position substitutions on binding to ACE2 and monoclonal or serum antibodies (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R29">29</xref>–<xref ref-type="bibr" rid="R32">32</xref>). While DMS has been very effective at single mutation profiling of the RBD, several widely circulating variants (e.g., beta, gamma and delta) as well as newly emerging variants [e.g., mu (B.1621) and lambda (C.37)] possess multiple mutations in the RBD, which are associated with enhanced ACE2 binding and/or multi-class antibody escape (<xref ref-type="bibr" rid="R18">18</xref>). Critically, the recent emergence of the omicron variant possessing 15 RBD mutations represents a substantial risk for immune evasion, thus underscoring the urgent need to determine the impact of combinatorial mutations. However, combinatorial sequence space grows exponentially as the number of mutations and amino acid diversity increases, rapidly outpacing the capabilities of experimental screening techniques. For instance, when focusing only on a subset of twenty RBD residues directly involved in ACE2 binding (<xref ref-type="bibr" rid="R33">33</xref>), theoretical sequence space (20<sup>20</sup> = 1 x 10<sup>26</sup>) far exceeds what can be screened by yeast display libraries (~10<sup>9</sup>). Here, we establish deep mutational learning (DML), which integrates experimental yeast display screening of RBD mutagenesis libraries with deep sequencing and machine learning (<xref ref-type="fig" rid="F1">Fig. 1</xref>). DML provides comprehensive interrogation of combinatorial RBD mutations and their impact on ACE2 binding and antibody escape, thus enabling predictive profiling of SARS-CoV-2 variants.</p>
<sec id="S2">
<title>Design and screening of RBD mutagenesis libraries</title>
<p id="P6">SARS-CoV-2 RBD mutagenesis libraries were targeted to a core region of the receptor-binding motif (RBM-2, positions 484-505), a subregion of the RBD that directly interfaces with ACE2 and where mutations are commonly observed in viral genome sequencing data [available on GISAID (<ext-link ext-link-type="uri" xlink:href="http://www.gsaid.org">http://www.gsaid.org</ext-link>)]. To generate training datasets covering a high mutational sequence space, a combinatorial mutagenesis scheme was designed based on DMS data for ACE2 binding, previously published by Starr et al. (<xref ref-type="bibr" rid="R29">29</xref>). Single mutation fitness values were empirically thresholded and converted to amino acid frequencies, with mutations below the ACE2 binding fitness threshold excluded. For each position, degenerate codons approximating the desired amino acid distribution were selected by minimizing mean-squared error (<xref ref-type="bibr" rid="R34">34</xref>) (some positions remained fixed due to their inability to tolerate mutations and retain ACE2 binding), resulting in a library with a theoretical amino acid diversity of 1.50 x 10<sup>10</sup> (library 2C) (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). An extended version of this library was also designed, with fully degenerate codons (NNK) at positions 417 and 439, which are mutated in a number of circulating variants and associated with antibody escape (<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>), resulting in a theoretical amino acid diversity of 5.99 x 10<sup>12</sup> (library 2CE). To generate training datasets covering a lower mutational sequence space, we constructed a tiling mutagenesis library, whereby fully degenerate codons (NNK) were tiled across three of the positions in RBM-2, resulting in a theoretical amino acid diversity of 1.53 x 10<sup>6</sup> (library 2T) (<xref ref-type="fig" rid="F2">Fig. 2b</xref>).</p>
<p id="P7">Synthetic oligonucleotides encoding the different libraries and spanning the region of interest were amplified by PCR to produce double-stranded DNA with homology to the full RBD sequence. Co-transformation of yeast (<italic>S. cerevisiae</italic> EBY100) with library-encoding DNA and linearized plasmid yielded more than 2 x 10<sup>7</sup> transformants for each library. RBD variants, displayed on the yeast surface as a C-terminal fusion to Aga2 (<xref ref-type="bibr" rid="R37">37</xref>), were isolated by fluorescence-activated cell sorting (FACS) based on binding to soluble human ACE2 receptor (Wu-Hu-1 RBD used as a guide for gating). RBD variants which showed a complete loss of binding to ACE2 were also isolated (<xref ref-type="fig" rid="F2">Fig. 2c</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Table 1</xref>). Importantly, this did not include variants with only partially reduced binding since such an intermediate population could not be assigned as binding or non-binding with sufficient confidence necessary for training supervised machine learning models. Targeted deep sequencing (Illumina) of the RBD gene was performed on all the sorted libraries; protein sequence logos revealed highly similar patterns of amino acid usage between the ACE2-binding and non-binding fractions (<xref ref-type="fig" rid="F2">Fig. 2d</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Table 2</xref>).</p>
<p id="P8">Next, using exclusively the ACE2-binding populations, FACS was performed to isolate variants that maintained binding or showed a complete loss of binding (escape) to four clinically used antibodies (LY-CoV16, LY-CoV555, REGN10933 and REGN10987). Wu-Hu-1 RBD was again used as a guide for gating antibody binding or escape (<xref ref-type="fig" rid="F2">Fig. 2e</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 1</xref>). The proportion of binding and escape (non-binding) for each antibody and library was highly variable, with REGN10933 having the lowest fraction of escape variants and LY-CoV555 having the highest (<xref ref-type="supplementary-material" rid="SD7">Supplementary Table 1</xref>). Deep sequencing was once again performed on antibody binding and escape fractions of all the sorted RBD libraries, and similar to ACE2, protein sequence logos of the two fractions looked highly similar (<xref ref-type="fig" rid="F2">Fig. 2f</xref>).</p>
</sec>
<sec id="S3">
<title>Machine learning models accurately predict ACE2 binding and antibody escape</title>
<p id="P9">Deep sequencing data from ACE2 selections underwent pre-processing, quality filtering and balancing steps to create the final training sets (<xref ref-type="sec" rid="S7">Methods</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 3</xref>, <xref ref-type="supplementary-material" rid="SD2">4</xref>). Following nucleotide to protein translation, amino acid sequences were converted to an input matrix by one-hot encoding (<xref ref-type="fig" rid="F3">Fig. 3a</xref>). Supervised machine learning models were trained for classification of ACE2 binding, which is defined as the probability (<italic>P</italic>) that any given RBD sequence binds to ACE2 (higher <italic>P</italic> correlates with binding). For initial benchmarking, a range of different baseline models (default parameters) were evaluated for their classification performance across several metrics (accuracy, F1, precision, recall). Machine learning models tested included K-nearest neighbor, logistic regression, naive Bayes, support vector machines, and random forests (RF); long-short term memory recurrent neural networks (RNN) were also trained, which are a class of deep learning models that have the ability to learn long-range dependencies in sequential data (<xref ref-type="bibr" rid="R38">38</xref>–<xref ref-type="bibr" rid="R41">41</xref>).</p>
<p id="P10">While all baseline models performed effectively (e.g., accuracy scores between 0.87 - 0.94), RF and RNN were selected for further optimization and application since they showed relatively higher performance metrics and could be trained faster (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 2</xref>). After hyperparameter optimization, the classification performance of both RF and RNN models was improved further, resulting in an area under ROC curve (AUC) values of 0.969 and 0.973, respectively (<xref ref-type="fig" rid="F3">Fig. 3b</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Table 5</xref>).</p>
<p id="P11">SARS-CoV-2 is evolving across a range of mutational trajectories, including variants such as omicron that rapidly accumulate mutations, as well variants that develop into lineages with subvariants (e.g., C.1, C.1.1, C.1.2) (<xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R43">43</xref>). Determining the performance of machine learning models across various mutational edit distances [Edit Distance (ED) from the reference Wu-Hu-1 RBD sequence] is therefore an important criterion. We thus examined model performance on test data that was divided into low mutational distances (≤ ED<sub>5</sub>), which corresponds to variants such as beta and gamma, and high mutational distances (≥ ED<sub>6</sub>), which corresponds to variants such as omicron. For both low and high distance variants, RF and RNN models showed high accuracy scores (&gt;94% and &gt;92% for low and high distances respectively) (<xref ref-type="fig" rid="F3">Fig. 3b</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 3a</xref>, <xref ref-type="supplementary-material" rid="SD3">Supplementary Tables 6</xref>, <xref ref-type="supplementary-material" rid="SD4">7</xref>).</p>
<p id="P12">Similar to the ACE2 selections, deep sequencing data from antibody selections was pre-processed, quality filtered, balanced and encoded as before. Supervised machine learning models (RF and RNN) were trained to classify antibody escape, which is defined as the probability that a given RBD sequence escapes a defined antibody (lower <italic>P</italic> correlates with escape). Following hyperparameter optimization, individual models trained for each of the four therapeutic antibodies displayed high performance metrics (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). Similar to ACE2 models, antibody escape models also showed high performance metrics across both low and high distance variants (<xref ref-type="supplementary-material" rid="SD3">Supplementary Tables 6</xref>, <xref ref-type="supplementary-material" rid="SD4">7</xref>). Closer examination revealed that it was crucial to combine training data from low distance libraries (2T) and high distance libraries (2C, 2CE) to achieve better performance for ACE2 and antibody escape models (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 3b</xref>).</p>
</sec>
<sec id="S4">
<title>Predictive profiling on synthetic lineage variants</title>
<p id="P13">Having established that ACE2 binding and antibody escape machine learning models can make highly accurate predictions on test data, we next evaluated their classification performance on defined variants, followed by experimental validation and structural modeling (<xref ref-type="fig" rid="F4">Fig. 4a</xref>). Synthetic lineages were generated <italic>in silico</italic> to simulate plausible evolutionary paths, where variants without predicted ACE2-binding intermediates at each mutational step were excluded. The lineages were designed to include variants at ED<sub>3</sub>, ED<sub>5</sub> and ED<sub>7</sub> from the original Wu-Hu-1 RBD sequence (nucleotide and amino acid). Additionally, the sequences were chosen to form lineages containing mutations observed in circulating variants (e.g., alpha: N501Y, beta/gamma: E484K and N501Y, kappa: E484Q and N501Y). ACE2 binding was predicted based on a consensus model, whereby a given RBD sequence is predicted to bind ACE2 when both RF and RNN models yield <italic>P</italic> &gt; 0.5, else they are predicted to be non-binders. The 46 synthetic lineage variants were chosen to contain diversity in ACE2 binding prediction (36 predicted binders, 10 predicted non-binders) (<xref ref-type="fig" rid="F4">Fig. 4b</xref>). Additionally, predictions for escape from each of the four therapeutic antibodies were made for the synthetic variants using a similar consensus model approach (RBD sequence escapes an antibody when both RF and RNN outputs are <italic>P</italic> &lt; 0.5) (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 4a–d</xref>). After having made all machine learning predictions, each synthetic RBD variant was individually expressed on the surface of yeast cells and assessed for ACE2 binding and antibody escape. The consensus model correctly predicted ACE2 binding for 91.67% (33/36) of the synthetic variants, with an accuracy of non-binding prediction of 100% (10/10), resulting in an overall prediction accuracy of 93.48% (43/46) (<xref ref-type="fig" rid="F4">Fig. 4b</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 5</xref>). For the 33 correctly predicted ACE2-binding variants, the combined accuracy of antibody escape predictions across all four therapeutic antibodies was 93.94% (124/132) (LY-CoV16: 31/33, LY-CoV555: 30/33, REGN10933: 31/33, REGN10987: 32/33) (<xref ref-type="fig" rid="F4">Fig. 4c</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 4a–d</xref>). Additionally, we identified three variants that were only ED<sub>3</sub> (nucleotide and amino acid) from the Wu-Hu-1 RBD and in which consensus models predicted ACE2 binding and escape from all four therapeutic antibodies. One of these variants possessed mutations in positions 493, 498 and 501, which are all mutated in the omicron variant. Subsequent yeast display experiments confirmed these machine learning predictions of antibody escape to all four therapeutic antibodies, including escape from the often mutation-resistant REGN10987 (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 6</xref>). Structural modeling by AlphaFold2 (<xref ref-type="bibr" rid="R44">44</xref>) was performed on eight synthetic RBD variants (all variants were accurately classified and experimentally validated for ACE2 binding or non-binding) (<xref ref-type="fig" rid="F4">Fig. 4d</xref>). The structural predictions showed that several ACE2 non-binding variants did not differ substantially from the original Wu-Hu-1 RBD. In contrast, the ACE2-binding variants showed a wide diversity of possible structural conformations.</p>
</sec>
<sec id="S5">
<title>Predictive profiling of current and prospective variants</title>
<p id="P14">In addition to the selected synthetic lineages, we also performed machine learning to predict ACE2 binding and antibody escape on a panel of 12 naturally-occurring variants of SARS-CoV-2 (<xref ref-type="supplementary-material" rid="SD5">Supplementary Table 8</xref>). We determined the accuracy of machine learning predictions on antibody escape by using, as a reference, the Stanford SARS-CoV-2 Susceptibility Database (<xref ref-type="bibr" rid="R24">24</xref>). Applying the same consensus model approach (RF and RNN) and thresholds as before, the prediction accuracy for ACE2 binding was 100% (12/12) and the prediction accuracy for escape across all four therapeutic antibodies was 85.42% (41/48) (antibody escape is defined here as a reported 30-fold reduced neutralization in the Stanford database). Strikingly, when applying a more stringent threshold for antibody escape prediction that requires both RF and RNN models to have high certainty in their prediction (both models <italic>P</italic> &lt; 0.25 for escape and <italic>P</italic> &gt; 0.75 for binding), 100% (30/30) of the machine learning predictions matched the results reported in the Stanford database.</p>
<p id="P15">Next, we used machine learning models to predict antibody escape on prospective ACE2-binding lineages at low mutational distances (ED<sub>1</sub> and ED<sub>2</sub>) from the Wu-Hu-1, alpha, beta, kappa, gamma and B.1.1523 RBD sequences. (<xref ref-type="fig" rid="F5">Fig. 5</xref>, <xref ref-type="supplementary-material" rid="SD7">Supplementary Figs. 7</xref>–<xref ref-type="supplementary-material" rid="SD6">9, Supplementary Table 9</xref>). Using a stringent threshold for antibody escape, we identified distinct patterns based on the starting variant. For example, REGN10933 and REGN10987 were largely resilient to escape from ED<sub>1</sub> lineages of Wu-Hu-1, alpha and kappa (<xref ref-type="fig" rid="F5">Fig. 5a–i</xref> and <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 7a–i</xref>). While ED<sub>1</sub> lineages of beta and gamma almost entirely escape both LY-CoV555 and LY-CoV16. A large fraction of ED<sub>2</sub> lineages from all variants escaped REGN10933, LY-CoV555 and LY-CoV16, revealing an increasing likelihood of escape with an increasing number of mutations. Notably, a small fraction (0.17%) of beta ED<sub>2</sub> lineages are predicted to escape all four therapeutic antibodies, whereby several of these variants possessed mutations in positions 417, 484, 493 and 501, which are all mutated in the omicron variant (<xref ref-type="fig" rid="F5">Fig. 5f</xref>). For further visualization, we constructed deep escape networks (<xref ref-type="fig" rid="F5">Fig. 5c, f, i</xref> and <xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 7c, f, i</xref>), depicting the vulnerability of the four therapeutic antibodies to low distance mutations (ED<sub>1</sub> and ED<sub>2</sub>). Specifically, deep escape networks illustrate the increase in sequence space per mutation while also pointing out the presence of mutations that vastly increase escape from multiple antibodies. For example, there are variants at ED<sub>1</sub> from Wu-Hu-1 that are predicted to not escape any of the four antibodies, however, just one additional mutation (ED<sub>2</sub>) can result in variants predicted to escape up to three antibodies.</p>
<p id="P16">Finally, DML enables rapid <italic>in silico</italic> evaluation of new variants that appear on genomic databases (GISAID). For example, we performed a similar analysis on the recently reported B.1.1.523 variant possessing RBD mutations E484K and S494P (<xref ref-type="bibr" rid="R45">45</xref>), which revealed complete escape from LY-CoV555 and ED<sub>1</sub> lineages, as well as substantial escape for other antibodies in ED<sub>2</sub> lineages, including three variants that escaped all four therapeutic antibodies (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 7g, h, i</xref>).</p>
</sec>
</sec>
<sec id="S6" sec-type="discussion">
<title>Discussion</title>
<p id="P17">For a multitude of reasons, eradication of SARS-CoV-2 appears improbable. Instead, an endemic future likely awaits (<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R47">47</xref>). An endemic and continually evolving SARS-CoV-2 poses a perpetual risk for the emergence of new variants that escape from vaccine- or infection-induced antibodies. In this study, we develop DML, a machine learning-guided protein engineering method for determining the impact of mutations in the SARS-CoV-2 RBD on ACE2 binding and antibody escape. In DML, machine learning models trained on thousands of classified RBD variants obtained from library screening make highly accurate predictions across a sequence space of billions of RBD variants, several orders of magnitude larger than what is possible from experimental screening alone. While we focused in this study on a subregion of the RBD associated with variants such as alpha, beta and gamma, this method can be expanded to incorporate mutations in additional regions across the RBD, which are associated with other variants and their corresponding lineages (e.g., omicron, delta, delta plus) (<xref ref-type="bibr" rid="R48">48</xref>).</p>
<p id="P18">DML could be used as a de facto monitoring system by rapidly and efficiently making predictions on genomic surveillance data of new variants, without the immediate need for experimental assays. This is especially crucial given the emergence of highly mutated variants such as omicron, where crucial public health decisions have to urgently be made, often before experimental assays of antibody escape or vaccine resistance can be performed.</p>
<p id="P19">By providing accurate predictions of antibody escape across a large mutational landscape, DML may enable researchers to select candidate antibody therapeutics and cocktails with the broadest efficacy against the spectrum of possible variants, some of which may occur simultaneously and may be highly mutated such as omicron. Assessing the efficacy of candidate antibodies against future variants puts therapeutic development on a proactive rather than reactive footing, potentially avoiding cases like LY-CoV555, which has lost efficacy to most variants of concern (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R24">24</xref>), resulting in the revocation of its clinical authorization as a monotherapy. Furthermore, such an approach could be used to guide the development of antibodies and cocktails that maximize breadth and potency (<xref ref-type="bibr" rid="R49">49</xref>, <xref ref-type="bibr" rid="R50">50</xref>) to both current and prospective variants. Finally, evidence exists that the receptor-binding domains of other endemic coronaviruses may be undergoing adaptive evolution to escape from human antibody responses (<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R52">52</xref>). Consequently, the application of DML to predict SARS-CoV-2 escape from polyclonal antibodies present in serum of vaccinated or convalescent individuals, combined with phylogenetic models of viral evolution (<xref ref-type="bibr" rid="R53">53</xref>), may enable the prospective identification of future variants with the highest likelihood of emergence and thus support vaccine development for COVID-19.</p>
</sec>
<sec id="S7" sec-type="materials | methods">
<title>Materials &amp; Methods</title>
<sec id="S8">
<title>Rational design of SARS-CoV-2 RBD mutagenesis libraries</title>
<sec id="S9">
<title>Combinatorial library design</title>
<p id="P20">The design of the combinatorial library 2C consisted of mutating residues within the RBM-2 region (positions 484-505 of the RBD) and was based on previously described results from deep mutational scanning (DMS) experiments (<xref ref-type="bibr" rid="R54">1</xref>). DMS enrichment ratios described by Starr et al. were thresholded to exclude mutations with decreased ACE2-binding fitness and then converted to amino acid frequencies as described previously (<xref ref-type="bibr" rid="R55">2</xref>). For each position, degenerate codons approximating the amino acid frequency distribution and diversity were selected, resulting in a library with a theoretical diversity of 1.50 x 10<sup>10</sup> amino acid sequences. Library 2CE consisted of the same combinatorial design in positions 484-505 but with additional fully degenerate codons (NNK) in positions 417 and 439, resulting in a theoretical amino acid diversity of 5.95 x 10<sup>12</sup>.</p>
</sec>
<sec id="S10">
<title>Tiling library design</title>
<p id="P21">The tiling library 2T was designed by incorporating three positions with full degenerate codons (NNK) within the RBM-2 (positions 484-505) of the RBD. The degenerate codons are tiled across such that the total sequences of a tiling library, i.e., the number of variants of up to a maximum edit distance (ED) <italic>k</italic> away from the wild-type sequence is determined by the length of sequence (<italic>n</italic>, here = 14 non-fixed positions in RBM-2), the number of NNKs (or max ED) introduced (<italic>k</italic>, here = 3) and the size of the alphabet (<italic>a</italic>, here = 20): <disp-formula id="FD1">
<mml:math id="M1">
<mml:mrow>
<mml:munderover>
<mml:mi>∑</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mi>k</mml:mi>
</mml:munderover>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mi>i</mml:mi>
</mml:msup>
<mml:mo>×</mml:mo>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtable columnalign="left" equalrows="true" equalcolumns="true">
<mml:mtr>
<mml:mtd>
<mml:mi>n</mml:mi>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mi>i</mml:mi>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p id="P22">Similarly, the number of sequences for a given ED <italic>k</italic> is given by: <disp-formula id="FD2">
<mml:math id="M2">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mi>k</mml:mi>
</mml:msup>
<mml:mo>×</mml:mo>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtable columnalign="left" equalrows="true" equalcolumns="true">
<mml:mtr>
<mml:mtd>
<mml:mi>n</mml:mi>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mi>k</mml:mi>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p id="P23">The resulting total diversity of the library 2T is 1,533,035 sequences.</p>
</sec>
</sec>
<sec id="S11">
<title>Cloning and expression of RBD mutagenesis libraries for yeast surface display</title>
<p id="P24">For libraries 2C and 2CE, synthetic single-stranded oligonucleotides (ssODNs) (Integrated DNA Technologies ultramers or oPools) were designed with degenerate codons spanning the region of interest and encoding the desired library diversity, with 30 bp overhangs on each end that were homologous to the yeast display plasmid pYD1. For library 2T, pools of ssODN were designed, where each member of the pool contains one combination of the three ‘NNK’ codons; in this case, consisting of 120 unique ssODNs. The ssODNs were amplified by PCR to produce double-stranded DNA. The plasmid pYD1 was modified such that the entire C-terminal fusion to Aga2 was replaced with a cassette encoding the RBD (Wu-Hu-1 sequence), expression tags and stop codon (HA Tag-RBD-FLAG-Stop). The RBM-2 residues 484-505 were replaced with an EcoRI recognition site, allowing production of a linearized vector with homology to mutagenesis ssODNs and with no parental background. Insert and EcoRI-linearized plasmids were concentrated and purified by silica spin columns (Zymo D4013) followed by drop dialysis for 1 hour in nuclease-free H2O (Millipore VSWP02500). The libraries were cloned and expressed in yeast by <italic>in vivo</italic> homologous recombination, as previously described (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>), using 1 μg each of plasmid and insert DNA per 300 μl of electrocompetent EBY100 cells in a 2 mm electroporation cuvette.</p>
</sec>
<sec id="S12">
<title>Screening RBD libraries for ACE2-binding and non-binding</title>
<p id="P25">Surface expression of SARS-Cov2 RBD was induced by growth in SG-UT medium at 23°C for 16-40 hours, as previously described (<xref ref-type="bibr" rid="R56">3</xref>). Approximately 10<sup>8</sup> library cells were washed once with 1 mL wash buffer (Dulbecco’s PBS+ 0.5% BSA + 0.1% Tween20 + 2 mM EDTA) by centrifugation at 8000 x g for 30 s. Washed cells were stained with 50 nM biotinylated human ACE2 (Acros AC2-H82E6) for 30 minutes at 4 °C, followed by an additional wash. Cells were then stained with 2.5 ng/μlstreptavidin-AlexaFluor 647 (Biolegend 405237) and 1 ng/μl anti-FLAG-PE (Biolegend 637310) for 30 minutes at 4 °C. Cells were subsequently pelleted by centrifugation at 8000 x g for 30s and kept on ice until sorting. Binding (ACE2+/FLAG+) and non-binding (ACE2-/FLAG+) cells were sorted by FACS (BD FACSAria Fusion or Sony MA800 cytometer) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Collected cells were cultured in SD-UT medium for one to two days at 30 °C. Induction and sorting was repeated until the desired populations were pure.</p>
</sec>
<sec id="S13">
<title>Screening RBD libraries for binding and escape to monoclonal antibodies</title>
<p id="P26">RBD libraries pre-sorted for ACE2-binding were cultured and induced, as described above. Induced cells were washed once with DPBS wash buffer, followed by incubation with 100 nM monoclonal antibody, or antibody mixtures. In the case of antibody mixtures, 100 nM of each antibody was used. Following an additional wash, cells were resuspended in 5 ng/μl anti-human IgG-AlexaFluor647 (Jackson Immunoresearch 109-605-098) and incubated for 30 minutes at 4°C. Cells were washed once more and resuspended in 1 ng/μl anti-FLAG-PE before 30 minutes of incubation at 4°C. Cells were then pelleted by centrifugation at 8000 x g for 30s and kept on ice until sorting. Cells expressing RBD that maintained antibody-binding (IgG+/FLAG+) or showed a complete loss of antibody binding (escape) (IgG-/FLAG+) were sorted by FACS (BD Aria Fusion or Sony MA800 instrument). Collected cells were cultured in SD-UT medium for 16-40 hours at 30 °C. Induction and sorting was repeated for multiple rounds until the desired populations of RBD variants showed purity for binding and escape (non-binding) to antibodies.</p>
</sec>
<sec id="S14">
<title>Antibody production and purification</title>
<p id="P27">Heavy chain and light chain inserts for REGN10933, REGN10987 (PDB: 6XDG) and LY-CoV16 (PDB: 7C01), LY-CoV555 (PDB: 7KMG) were cloned into pTwist transient expression vectors by Gibson Assembly. 30 mL cultures of Expi293 cells (Thermo, A14635) were transfected according to the manufacturer’s instructions. After 5-7 days, dense Expi293 cultures were centrifuged at 300 x g for 5 minutes to pellet the cells. Supernatant was filtered using Steriflip® 0.22 μm (Merck, SCGP00525) filter units. Using protein G purification, Expi supernatant was directly loaded onto Protein G Agarose (Pierce, Cat# 20399) gravity columns, washed twice with PBS and eluted using Protein G Elution Buffer (Pierce, Cat# 21004). The eluted fractions were immediately neutralized with 1M TRIS-Buffer (pH 8) to physiological pH and quantified by Nanodrop™ 2000c for A280 nm absorption. Protein containing fractions were pooled and buffer exchanged using SnakeSkin™ dialysis tubing (10 MWCO, Pierce Cat#68100) followed by further dialysis and concentration using Amicon Ultra-4 10kDa centrifugal units (Merck, Cat# UFC801096), as described previously (<xref ref-type="bibr" rid="R58">5</xref>).</p>
</sec>
<sec id="S15">
<title>Deep sequencing of RBD libraries</title>
<p id="P28">Plasmid DNA encoding the RBD variants was isolated following the manufacturer’s instructions (Zymo D2004). Mutagenized regions of the RBD were amplified using custom oligonucleotides. Illumina Nextera barcode sequences were added in a second PCR amplification step, allowing for multiplexed high-throughput sequencing runs. Populations were pooled at the desired ratios and sequenced using Illumina 2 x 250 PE or 2 x 150 PE protocols (MiSeq or NovaSeq instruments).</p>
</sec>
<sec id="S16">
<title>Processing of deep sequencing data, statistical analysis and plots</title>
<sec id="S17">
<title>Data preprocessing</title>
<p id="P29">Sequencing reads were paired, quality trimmed and assembled using Geneious and BBDuk, with a quality threshold of qphred ≥ 25. Mutagenized regions of interest were then extracted using custom Python scripts, followed by translation to amino acid sequences. The sequences obtained from each of the three libraries (2C, 2CE and 2T) were pre-processed separately before being combined into the final training set used for model training and evaluation. To remove sequencing errors, all libraries were filtered for sequences complying with the initial degenerate codon mutagenesis scheme. Library 2CE was filtered for only those sequences retaining unmutated residues in positions 417/439, to focus on the 484-505 region. Next, library 2T was filtered using a threshold of read counts &gt; 4 and restricted to sequences that were ≤ ED<sub>3</sub> from Wu-Hu-1 RBD sequence.</p>
<p id="P30">Duplicate sequences in the full dataset were removed and a balanced dataset was created from the remaining data such that equal numbers of positive (binding) and negative class (non-binding) sequences were present for each ED. We observed significant bias in model performance when predictions are separated by ED from the Wu-Hu-1 RBD sequence, which was likely due to class imbalance in the training data. Class balancing was thus performed through random subsampling from the majority class at each ED equal to the counts from the minority class. Those that were not sampled from the majority class were then reserved separately as additional “unseen sequences”. These were then used for model evaluation to ensure that the models could generalize well even to the sequences removed during balancing.</p>
</sec>
<sec id="S18">
<title>Statistical analysis and plots</title>
<p id="P31">Statistical analysis was performed using R 4.0.1 (<xref ref-type="bibr" rid="R59">6</xref>) and Python 3.8.5 (<xref ref-type="bibr" rid="R60">7</xref>). Graphics were generated using the ggplot2 3.3.3 (<xref ref-type="bibr" rid="R61">8</xref>), ComplexHeatmap 2.4.3 (<xref ref-type="bibr" rid="R62">9</xref>) pheatmap 1.0.12 (<xref ref-type="bibr" rid="R63">10</xref>), igraph 1.2.6 (<xref ref-type="bibr" rid="R64">11</xref>), RCy3 2.8.1 (<xref ref-type="bibr" rid="R65">12</xref>), stringr 1.4.0 (<xref ref-type="bibr" rid="R66">13</xref>), dplyr 1.0.6 (<xref ref-type="bibr" rid="R67">14</xref>), and RColorBrewer 1.1-2 (<xref ref-type="bibr" rid="R68">15</xref>) R package.</p>
</sec>
<sec id="S19">
<title>Escape Networks</title>
<p id="P32">Network plots were generated using the igraph package 1.2.6 (<xref ref-type="bibr" rid="R64">11</xref>) and Cytoscape software 3.8.2 (<xref ref-type="bibr" rid="R69">16</xref>) with edges drawn between every pair of two amino acid sequences from ED 1 and 2, when the pair of sequences share a common mutation on amino acid level. Edges were colored according to the change in number of antibodies that escape. Nodes representing RBD variant sequences were clustered and colored according to the number of antibodies that escape, and the mutational distance from the reference sequence.</p>
</sec>
</sec>
<sec id="S20">
<title>Machine learning model training and evaluation</title>
<p id="P33">All machine learning (ML) classifier models were built in Python (3.8.5) (<xref ref-type="bibr" rid="R60">7</xref>). Data was prepared and visualized using numpy (1.19.2), matplotlib (3.3.4), and pandas (1.2.4). Random Forest (RF) and other benchmarking ML models were built using Scikit-Learn (0.24.2), a 80/20 train-test data split (random split) to train baseline models, and a 90/10 traintest data split (random split) for final RF and RNN models. Keras libraries (2.4.3) from Tensorflow (v2.5) were used to build the long-short-term-memory recurrent neural networks (RNN) models.</p>
<p id="P34">RBD sequences were one-hot encoded prior to being used as inputs into the models. For the RNN, the 2D one-hot encoded matrix was used as the input, while for all other models, the matrix was flattened into a single dimensional vector beforehand. After selecting the best models, hyperparameter optimization was performed to further improve the performance of the chosen RF and RNN models using 50 rounds of Random Search with 5-fold cross-validation while scoring based on precision. All RF models were further calibrated using both the “isotonic” and Platt scaling (<xref ref-type="bibr" rid="R70">17</xref>–<xref ref-type="bibr" rid="R72">19</xref>), and the best model from the three was selected by calculating the overall mean-square error (MSE) from the true labels, with the RF model with the lowest MSE selected as the final model. For evaluation of the models on the held-out test set, models were evaluated on the basis of Accuracy, F1, Precision, Recall, and AUC-ROC curve using the entire test set. For further detailed evaluation, the test data was separated into two distances: low and high distance sequence sets, which consisted only of sequences ≤ ED<sub>5</sub> or ≥ ED<sub>6</sub> from Wu-Hu-1 RBD sequence, respectively. These two sets were then used to evaluate the accuracy, F1, Precision, and Recall of models to investigate any performance bias at different distances. The accuracy of the models were also evaluated on the sequences reserved during dataset balancing (‘unseen sequences’) separated similarly by ED.</p>
</sec>
<sec id="S21">
<title>
<italic>In silico</italic> sequence generation and evaluation</title>
<p id="P35">Synthetic RBD variant sequences were generated <italic>in silico</italic> using custom Python scripts for selected edit distances (ED) from the Wu-Hu-1 RBD sequence. The ED was defined on both the nucleotide and amino acid level, such that each generated nucleotide sequence was categorized by an ED pair (distance_nt, distance_aa). The synthetic variants (<italic>in silico</italic> generated sequences) were evaluated for their probability of ACE2-binding and non-binding using a consensus model (RF and RNN) approach. For a given RBD sequence, ACE2-binding prediction was defined as the case where both models output <italic>P</italic> &gt; 0.5, else the sequence was considered as ACE2 non-binding. Similarly, the sequences were evaluated for binding and escape (non-binding) from monoclonal antibodies. Here the sequences were categorized into one of four categories: escape (both models <italic>P</italic> &lt;0.25), antibody binding (both models <italic>P</italic> &gt;0.75), unsure (at least one model gives <italic>P</italic> between 0.25 and 0.75), and disagree (one model outputs <italic>P</italic> &lt;0.25 while the other model outputs a <italic>P</italic> &gt;0.75).</p>
</sec>
<sec id="S22">
<title>Experimental validation of selected RBD variants for ACE2-binding and antibody escape</title>
<p id="P36">Individual sequences for RBD variants were ordered as complementary forward and reverse primers (Integrated DNA Technologies) in 96-well plates A single round of annealing and extension was used to produce double-stranded DNA with 14-bp of homology at 5’ and 3’ ends to the pYD1-RBD entry vector, followed by Gibson Assembly with EcoRI digested vector. Plasmids were transformed into EBY100 prepared with the Frozen-EZ Yeast Transformation Kit II (Zymo) and plated on SD-UT agar. Individual colonies were picked and grown in SD-UT liquid medium overnight at 30°C, then diluted to OD600 = 0.5 in SG-UT medium and grown for 40-48 hours at 23°C. Cells were stained with biotinylated ACE2 or purified antibody as described above. Flow cytometry analysis was performed on the BD Fortessa cytometer.</p>
</sec>
<sec id="S23">
<title>Structural Prediction of RBD variants by AlphaFold2</title>
<p id="P37">Structural predictions were generated with the Alphafold v2.1.0 public iPython notebook using residues 331-530 of the spike protein.</p>
<p id="P38">(<ext-link ext-link-type="uri" xlink:href="https://colab.research.google.com/github/deepmind/alphafold/blob/main/notebooks/AlphaFold.ipynb">https://colab.research.google.com/github/deepmind/alphafold/blob/main/notebooks/AlphaFold.ipynb</ext-link>) (<xref ref-type="bibr" rid="R73">20</xref>). Results were visualized and aligned in PyMol v2.2.3 (<xref ref-type="bibr" rid="R74">21</xref>).</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>STable 3</label>
<media xlink:href="EMS141119-supplement-STable_3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66904" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>STable 4</label>
<media xlink:href="EMS141119-supplement-STable_4.zip" mimetype="application" mime-subtype="zip" id="N66913" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD3">
<label>STable 6</label>
<media xlink:href="EMS141119-supplement-STable_6.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66922" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD4">
<label>STable 7</label>
<media xlink:href="EMS141119-supplement-STable_7.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66931" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD5">
<label>STable 8</label>
<media xlink:href="EMS141119-supplement-STable_8.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66940" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD6">
<label>STable 9</label>
<media xlink:href="EMS141119-supplement-STable_9.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66949" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD7">
<label>Supplementary Material</label>
<media xlink:href="EMS141119-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66958" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S24">
<title>Acknowledgements</title>
<p>We thank the ETH Zurich D-BSSE Single Cell Unit and the Genomics Facility Basel for support.</p>
<sec id="S25">
<title>Funding</title>
<p>This work was supported by the Botnar Research Centre for Child Health (FTC Covid-19, to STR).</p>
</sec>
</ack>
<sec id="S26" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P39">The main data supporting the results in this study are available within the paper and its Supplementary Information.</p>
</sec>
<fn-group>
<fn id="FN2" fn-type="con">
<p id="P40">
<bold>Author contributions</bold>
</p>
<p id="P41">Conceptualization: JMT, CRW, BG, RAE and STR. Experimental methodology: JMT, RAE and LF. Computational methodology: JMT, CRW, BG, SWM, JH, AY. Supervision: JMT, CRW and STR. Writing - original draft: JMT, CRW, BG, RAE and STR. Writing - review &amp; editing: all authors.</p>
</fn>
<fn id="FN3" fn-type="conflict">
<p id="P42">
<bold>Competing interests</bold>
</p>
<p id="P43">ETH Zurich has filed for patent protection on the technology described herein, and JMT, CRW, BG, RAE and STR. are named as co-inventors. CRW is an employee of deepCDR Biologics. CRW and STR are co-founders and may hold shares of deepCDR Biologics.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iketani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>130</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Groß</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hörnich</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Krüger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Graichen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hofmann-Winkler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kempf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>MS</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2384</fpage>
<lpage>2393</lpage>
<elocation-id>e12</elocation-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wibmer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hermanus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madzivhandila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kgagudi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oosthuysen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lambson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vermeulen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Berg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rossouw</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>622</fpage>
<lpage>625</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Beltran</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Nitido</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pavlovic</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Poznansky</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sigal</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2372</fpage>
<lpage>2383</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontanet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Autran</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lina</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kieny</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Karim</surname>
<given-names>SSA</given-names>
</name>
<name>
<surname>Sridhar</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 variants and ending the COVID-19 pandemic</article-title>
<source>The Lancet</source>
<volume>397</volume>
<fpage>952</fpage>
<lpage>954</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y-M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z-G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Z-W</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Y-Y</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M-L</given-names>
</name>
<etal/>
</person-group>
<article-title>A new coronavirus associated with human respiratory disease in China</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>265</fpage>
<lpage>269</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormick</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mellors</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>The emerging plasticity of SARS-CoV-2</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<fpage>1306</fpage>
<lpage>1308</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1444</fpage>
<lpage>1448</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Tuekprakhon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nutalai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2348</fpage>
<lpage>2361</lpage>
<elocation-id>e6</elocation-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Key residues of the receptor binding motif in the spike protein ofSARS-CoV-2 that interact with ACE2 and neutralizing antibodies</article-title>
<source>Cell Mol Immunol</source>
<year>2020</year>
<volume>17</volume>
<fpage>621</fpage>
<lpage>630</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Nutalai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tuekprakhon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2201</fpage>
<lpage>2211</lpage>
<elocation-id>e7</elocation-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>6103</elocation-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nielsen</surname>
<given-names>SCA</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>KJL</given-names>
</name>
<name>
<surname>Hoh</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Röltgen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jean</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Rustagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>AE</given-names>
</name>
<etal/>
</person-group>
<article-title>sHuman B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
<volume>28</volume>
<fpage>516</fpage>
<lpage>525</lpage>
<elocation-id>e5</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>SCA</given-names>
</name>
<name>
<surname>Hoh</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Röltgen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wirz</surname>
<given-names>OF</given-names>
</name>
<name>
<surname>Haraguchi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jean</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>KJL</given-names>
</name>
<name>
<surname>Roskin</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues</article-title>
<source>Science</source>
<year>2021</year>
<volume>372</volume>
<fpage>738</fpage>
<lpage>741</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Reidy</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Trivette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Suryadevara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>1422</fpage>
<lpage>1427</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Huey-Tubman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>MAG</given-names>
</name>
<name>
<surname>Sharaf</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Koranda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gristick</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.025</pub-id>
<comment>0</comment>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>The antigenic anatomy of SARS-CoV-2 receptor binding domain</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2183</fpage>
<lpage>2200</lpage>
<elocation-id>e22</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Carabelli</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ludden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>
<source>Nat Rev Microbiol</source>
<year>2021</year>
<fpage>1</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wloga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Wloga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Copin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lanza</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Negron</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies</article-title>
<source>Science</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1126/science.abd0831</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>120</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016</article-title>
<source>Cell Rep Med</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100255</pub-id>
<comment>0</comment>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Culap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<fpage>1</fpage>
<lpage>10</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzou</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nouhin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rhee</surname>
<given-names>S-Y</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parkin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shafer</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<elocation-id>1006</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>ter Meulen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van den Brink</surname>
<given-names>ENL</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Marissen</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>CSW</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>AQ</given-names>
</name>
<name>
<surname>Bogaards</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Deventer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Preiser</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</article-title>
<source>PLoS Med</source>
<year>2006</year>
<volume>3</volume>
<elocation-id>e237</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CCD</given-names>
</name>
<name>
<surname>So</surname>
<given-names>RTY</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>CKP</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>IA</given-names>
</name>
</person-group>
<article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>630</fpage>
<lpage>633</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2</article-title>
<source>Science</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1126/science.abc2241</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowler</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Deep mutational scanning: a new style of protein science</article-title>
<source>Nat Methods</source>
<year>2014</year>
<volume>11</volume>
<fpage>801</fpage>
<lpage>807</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>King</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310</lpage>
<elocation-id>e20</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Addetia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hannon</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Prospective mapping of viral mutations that escape antibodies usedto treat COVID-19</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<fpage>850</fpage>
<lpage>854</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<etal/>
</person-group>
<article-title>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>44</fpage>
<lpage>57</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>463</fpage>
<lpage>476</lpage>
<elocation-id>e6</elocation-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Parola</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Greiff</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis</article-title>
<source>Nucleic Acids Res</source>
<year>2018</year>
<pub-id pub-id-type="doi">10.1093/nar/gky550</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomson</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Spreafico</surname>
<given-names>R</given-names>
</name>
<name>
<surname>da Silva Filipe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wojcechowskyj</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Piccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pascall</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Dillen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lytras</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>1171</fpage>
<lpage>1187</lpage>
<elocation-id>e20</elocation-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>K-C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y-C</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>T-S</given-names>
</name>
</person-group>
<article-title>Comprehensive Deep Mutational Scanning Reveals the Immune-EscapingHotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies</article-title>
<source>Front Microbiol</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>1812</elocation-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boder</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Wittrup</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>Yeast surface display for screening combinatorial polypeptide libraries</article-title>
<source>Nat Biotechnol</source>
<year>1997</year>
<volume>15</volume>
<fpage>553</fpage>
<lpage>557</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hochreiter</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmidhuber</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Long Short-Term Memory</article-title>
<source>Neural Comput</source>
<year>1997</year>
<volume>9</volume>
<fpage>1735</fpage>
<lpage>1780</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Friedensohn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Jordi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ehling</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bonati</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dahinden</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gainza</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>BE</given-names>
</name>
<etal/>
</person-group>
<article-title>Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning</article-title>
<source>Nat Biomed Eng</source>
<year>2021</year>
<fpage>1</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kakuzaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Metsugi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kashiwagi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsunoda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Teramoto</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Antibody design using LSTM based deep generative model from phage display library for affinity maturation</article-title>
<source>Sci Rep</source>
<year>2021</year>
<volume>11</volume>
<elocation-id>5852</elocation-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Widrich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pavlović</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chernigovskaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Snapkov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Slabodkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>BB</given-names>
</name>
<etal/>
</person-group>
<source>bioRxiv</source>
<pub-id pub-id-type="doi">10.1101/2021.07.08.451480</pub-id>
<comment>in press</comment>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giovanetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>San</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Lessells</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cuadros</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Zekri</surname>
<given-names>A-RN</given-names>
</name>
<name>
<surname>Sangare</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Ouedraogo</surname>
<given-names>A-S</given-names>
</name>
<etal/>
</person-group>
<article-title>A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa</article-title>
<source>Science</source>
<year>2021</year>
<volume>374</volume>
<fpage>423</fpage>
<lpage>431</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheepers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Everatt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Amoako</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Mnguni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mahlangu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wibmer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>San</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection</article-title>
<year>2021</year>
<elocation-id>2021.08.20.21262342</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.08.20.21262342</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jumper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pritzel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Figurnov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ronneberger</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tunyasuvunakool</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Žídek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Potapenko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bridgland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Highly accurate protein structure prediction with AlphaFold</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<fpage>583</fpage>
<lpage>589</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Veer</surname>
<given-names>BMJW</given-names>
</name>
<name>
<surname>Dingemans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Alphen</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Hoebe</surname>
<given-names>CJPA</given-names>
</name>
<name>
<surname>Savelkoul</surname>
<given-names>PHM</given-names>
</name>
</person-group>
<article-title>A novel B.1.1.523 SARS-CoV-2 variant that combines many spike mutations linked to immune evasion with current variants of concern</article-title>
<year>2021</year>
<elocation-id>2021.09.16.460616</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.09.16.460616</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Halloran</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Transition to endemicity: Understanding COVID-19</article-title>
<source>Immunity</source>
<year>2021</year>
<volume>54</volume>
<fpage>2172</fpage>
<lpage>2176</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>The coronavirus is here to stay — here’s what that means</article-title>
<source>Nature</source>
<year>2021</year>
<volume>590</volume>
<fpage>382</fpage>
<lpage>384</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Veyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baidaliuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Staropoli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Guivel-Benhassine</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rajah</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Planchais</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Porrot</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<fpage>276</fpage>
<lpage>280</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Addetia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Marzi</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape</article-title>
<source>Nature</source>
<year>2021</year>
<volume>597</volume>
<fpage>97</fpage>
<lpage>102</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bedinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schendel</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Dennison</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rayaprolu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zandonatti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diaz Avalos</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study</article-title>
<source>Science</source>
<year>2021</year>
<volume>374</volume>
<fpage>472</fpage>
<lpage>478</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kistler</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e</article-title>
<source>eLife</source>
<year>2021</year>
<volume>10</volume>
<elocation-id>e64509</elocation-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eguia</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Stevens-Ayers</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kelnhofer-Millevolte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Greninger</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Boeckh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>A human coronavirus evolves antigenically to escape antibody immunity</article-title>
<source>PLOS Pathog</source>
<year>2021</year>
<volume>17</volume>
<elocation-id>e1009453</elocation-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worobey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pekar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Joy</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suchard</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wertheim</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Lemey</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The emergence of SARS-CoV-2 in Europe and North America</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>564</fpage>
<lpage>570</lpage>
</element-citation>
</ref>
<ref id="R54">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>King</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310</lpage>
<elocation-id>e20</elocation-id>
</element-citation>
</ref>
<ref id="R55">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Parola</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Greiff</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis</article-title>
<source>Nucleic Acids Res</source>
<year>2018</year>
<volume>46</volume>
<fpage>7436</fpage>
<lpage>7449</lpage>
</element-citation>
</ref>
<ref id="R56">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boder</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Wittrup</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>Yeast surface display for screening combinatorial polypeptide libraries</article-title>
<source>Nat Biotechnol</source>
<year>1997</year>
<volume>15</volume>
<fpage>553</fpage>
<lpage>557</lpage>
</element-citation>
</ref>
<ref id="R57">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Hackel</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sazinsky</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Lippow</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wittrup</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>Isolating and engineering human antibodies using yeast surface display</article-title>
<source>Nat Protoc</source>
<year>2006</year>
<volume>1</volume>
<fpage>755</fpage>
<lpage>768</lpage>
</element-citation>
</ref>
<ref id="R58">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazquez-Lombardi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nevoltris</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Luthra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schofield</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Christ</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Transient expression of human antibodies in mammalian cells</article-title>
<source>Nat Protoc</source>
<year>2018</year>
<volume>13</volume>
<fpage>99</fpage>
<lpage>117</lpage>
</element-citation>
</ref>
<ref id="R59">
<label>6</label>
<element-citation publication-type="book">
<collab>R Core Team</collab>
<source>R: A Language and Environment for Statistical Computing</source>
<publisher-name>R Foundation for Statistical Computing</publisher-name>
<publisher-loc>Vienna, Austria</publisher-loc>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R60">
<label>7</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rossum</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Drake</surname>
<given-names>FL</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<source>The Python Language Reference Manual</source>
<publisher-name>Network Theory Ltd</publisher-name>
<year>2011</year>
</element-citation>
</ref>
<ref id="R61">
<label>8</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wickham</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>ggplot2: Elegant Graphics for Data Analysis</source>
<publisher-name>Springer-Verlag</publisher-name>
<publisher-loc>New York</publisher-loc>
<year>2009</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://ggplot2.org">http://ggplot2.org</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R62">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Eils</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schlesner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>
<source>Bioinforma Oxf Engl</source>
<year>2016</year>
<volume>32</volume>
<fpage>2847</fpage>
<lpage>2849</lpage>
</element-citation>
</ref>
<ref id="R63">
<label>10</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Kolde</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>pheatmap: Pretty Heatmaps</source>
<year>2019</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=pheatmap">https://CRAN.R-project.org/package=pheatmap</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R64">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nepusz</surname>
<given-names>T</given-names>
</name>
</person-group>
<collab>Complex Systems</collab>
<article-title>The igraph software package for complex network research</article-title>
<source>Inter Journal</source>
<year>2006</year>
<elocation-id>1695</elocation-id>
</element-citation>
</ref>
<ref id="R65">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustavsen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Isserlin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Demchak</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pico</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>RCy3: Network biology using Cytoscape from within R</article-title>
<year>2019</year>
<pub-id pub-id-type="doi">10.12688/f1000research.20887.3</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>13</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Wickham</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>stringr: Simple, Consistent Wrappers for Common String Operations</source>
<year>2019</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=stringr">https://CRAN.R-project.org/package=stringr</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R67">
<label>14</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Wickham</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>K</given-names>
</name>
</person-group>
<source>dplyr: A Grammar of Data Manipulation</source>
<year>2021</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=dplyr">https://CRAN.R-project.org/package=dplyr</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R68">
<label>15</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Neuwirth</surname>
<given-names>E</given-names>
</name>
</person-group>
<source>RColorBrewer: ColorBrewer Palettes</source>
<year>2014</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=RColorBrewer">https://CRAN.R-project.org/package=RColorBrewer</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R69">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Markiel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ozier</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schwikowski</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ideker</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
<source>Genome Res</source>
<year>2003</year>
<volume>13</volume>
<fpage>2498</fpage>
<lpage>2504</lpage>
</element-citation>
</ref>
<ref id="R70">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Platt</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Probabilistic Outputs for Support Vector Machines and Comparisons to Regularized Likelihood Methods</article-title>
<source>Adv Large Margin Classif</source>
<year>2000</year>
<volume>10</volume>
</element-citation>
</ref>
<ref id="R71">
<label>18</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Bostrom</surname>
<given-names>H</given-names>
</name>
</person-group>
<conf-name>2008 Seventh International Conference on Machine Learning and Applications</conf-name>
<conf-sponsor>IEEE</conf-sponsor>
<conf-loc>San Diego, CA, USA</conf-loc>
<year>2008</year>
<fpage>121</fpage>
<lpage>126</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://ieeexplore.ieee.org/document/4724964/">http://ieeexplore.ieee.org/document/4724964/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R72">
<label>19</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Niculescu-Mizil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Caruana</surname>
<given-names>R</given-names>
</name>
</person-group>
<conf-name>Proceedings of the 22nd international conference on Machine learning - ICML ‘05</conf-name>
<conf-sponsor>ACM Press</conf-sponsor>
<conf-loc>Bonn, Germany</conf-loc>
<year>2005</year>
<fpage>625</fpage>
<lpage>632</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://portal.acm.org/citation.cfm?doid=1102351.1102430">http://portal.acm.org/citation.cfm?doid=1102351.1102430</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R73">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jumper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pritzel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Figurnov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ronneberger</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tunyasuvunakool</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zadek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Potapenko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bridgland</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Highly accurate protein structure prediction with AlphaFold</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<fpage>583</fpage>
<lpage>589</lpage>
</element-citation>
</ref>
<ref id="R74">
<label>21</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Schrodinger</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DeLano</surname>
<given-names>W</given-names>
</name>
</person-group>
<source>PyMOL</source>
<year>2020</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/pymol">http://www.pymol.org/pymol</ext-link>
</comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Overview of deep mutational learning of the RBD for prediction of ACE2 binding and antibody escape.</title>
<p>The RBD or the SARS-CoV-2 spike protein is expressed on the surface of yeast, mutagenesis libraries are designed on the receptor-binding motif (RBM-2) of the RBD, which are the sites of interaction with ACE2 and neutralizing antibodies (e.g., therapeutic antibody drugs). RBD libraries are screened by FACS for binding to ACE2 and neutralizing antibodies, both binding and non-binding (escape) populations are isolated and subjected to deep sequencing. Machine learning models are trained to predict binding status to ACE2 or antibodies based on RBD sequence. Machine learning models are then used to predict ACE2 binding and antibody escape on current and prospective variants and lineages.</p>
</caption>
<graphic xlink:href="EMS141119-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Design of RBD mutagenesis libraries and screening by yeast surface display and deep sequencing.</title>
<p>
<bold>a</bold>, Shown is the amino acid usage in positions RBM-2 (484-505 of the RBD), which was based on DMS data for ACE2 binding (<xref ref-type="bibr" rid="R29">29</xref>) and used to design the combinatorial library 2C. <bold>b</bold>, Shown are representative examples of degenerate codons tiled across RBM-2, which are pooled together to comprise library 2T. <bold>c</bold>, Flow cytometry dot plots depict yeast display screening of RBD libraries (2C, 2CE and 2T) and control RBD (Wu-Hu-1); gating schemes correspond to selection of ACE2-binding and non-binding variants. <bold>d</bold>, Amino acid logo plots of the RBD are based on deep sequencing data from ACE2-binding and non-binding selections. <bold>e</bold>, Flow cytometry dot plots depict yeast display screening of pooled RBD libraries (2C and 2CE) that were pre-selected for ACE2 binding; gating schemes correspond to selection of variants for binding and escape (non-binding) to four therapeutic monoclonal antibodies (mAbs). <bold>f</bold>, Amino acid logo plots of the RBD are based on deep sequencing data from antibody-binding and escape selections.</p>
</caption>
<graphic xlink:href="EMS141119-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Training and testing of machine and deep learning models for prediction of ACE2 binding and antibody escape based on RBD sequence.</title>
<p>
<bold>a</bold>, Deep sequencing data from ACE2 and monoclonal antibody (mAb) selections is encoded by one-hot encoding and used to train supervised machine learning (e.g., Random Forest, RF) and deep learning models (e.g., recurrent neural network, RNN). Models perform classification by predicting a probability (<italic>P</italic>) of ACE2 binding or non-binding and mAb binding or escape (non-binding) based on the RBD sequence. <bold>b</bold> and <bold>c</bold>, Performance of fully trained and optimized RF and RNN models for prediction of ACE2 binding and antibody escape on test data is shown with ROC curves and accuracy graphs. Low and high distance sequences are defined as those ≤ED<sub>5</sub> and ≥ED<sub>6</sub> from Wu-Hu-1 RBD, respectively.</p>
</caption>
<graphic xlink:href="EMS141119-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Prediction and experimental validation of synthetic lineages of RBD variants.</title>
<p>
<bold>a</bold>, Workflow to select and test synthetic variants at chosen edit distances (ED<sub>3</sub>, ED<sub>5</sub>, and ED<sub>7</sub>) from Wu-Hu-1 RBD. <bold>b</bold>, Lineage plot of synthetic variants depicts machine learning predictions and experimental validation (<xref ref-type="supplementary-material" rid="SD7">Supplementary Fig. 5</xref>) for ACE2 binding and non-binding. <bold>c</bold>, Dot plots of synthetic variants correspond to machine learning model (RF and RNN) predictions and experimental validation for antibody binding or escape. <bold>d</bold>, Structural modeling by AlphaFold2 shows predicted structures of RBD variants that are ACE2 binding (green boxes) or non-binding (red boxes); control is Wu-Hu-1 RBD (black box).</p>
</caption>
<graphic xlink:href="EMS141119-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Predictive profiling of selected RBD variants for antibody escape across low mutational distances.</title>
<p>
<bold>a, d, g</bold>, Heatmap depicts monoclonal antibody (mAb) binding as assessed by RF and RNN models of ED<sub>1</sub> and ED<sub>2</sub> variants of alpha, beta and kappa. <bold>b, e, h</bold>, The number of sequences escaping a combination of <italic>n</italic> (number) mAbs for ED<sub>1</sub> and ED<sub>2</sub> (agreement between models, threshold &gt;0.5). <bold>c, f, i</bold>, Deep escape networks display possible evolutionary paths between variants and their escape from mAbs.</p>
</caption>
<graphic xlink:href="EMS141119-f005"/>
</fig>
</floats-group>
</article>
